Back to Search

Pilot Study of Glofitamab and Lenalidomide in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with a BTK Inhibitor

  • Protocol Number: 202404154
  • Principal Investigator: Patel, Dilan
  • Cancer Types: Lymphoma

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

The purpose of this study is to find out whether the combination of glofitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma

Protocol Interventions

Drug: Glofitamab, Drug: Obinutuzumab, Drug: Lenalidomide